The role of macrophage lineage cells in kidney graft rejection and survival

Transplantation

Volumn 94, Issue 4, 2012, Pages 309-318

  Rowshani, Ajda Tahereh ^a   Vereyken, Elly Johanna Francisca ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Kidney graft survival; Kidney transplantation; Macrophages; Monocytes; Rejection

Indexed keywords

CELL FUNCTION; CELL LINEAGE; CELL MIGRATION; CELL POLARITY; CELLULAR DISTRIBUTION; DENDRITIC CELL; DISEASE MARKER; GRAFT SURVIVAL; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL LINEAGE; CELL MOVEMENT; CELL POLARITY; DENDRITIC CELLS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MACROPHAGES; MONOCYTES;

EID: 84865656594     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318250c10f     Document Type: Review

References (123)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
3. Brent L, Brown J, Medawar PB. Skin transplantation immunity in relation to hypersensitivity. Lancet 1958; 2: 561.
4. Girlanda R, Kleiner DE, Duan Z, et al. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008; 8: 600.
5. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68: 1866.
6. Barratt-Boyes SM, Thomson AW. Dendritic cells: tools and targets for transplant tolerance. Am J Transplant 2005; 5: 2807.
7. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610.
8. Wyburn KR, Jose MD, Wu H, et al. The role of macrophages in allograft rejection. Transplantation 2005; 80: 1641.
9. Chadban SJ, Wu H, Hughes J. Macrophages and kidney transplantation. Semin Nephrol 2010; 30: 278.
10. Volkman A, Gowans JL. The origin ofmacrophages from bone marrow in the rat. Br J Exp Pathol 1965; 46: 62.
11. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656.
12. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121: 2437.
13. Van Furth R, Diesselhoff-den Dulk MC, Mattie H. Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med 1973; 138: 1314.
14. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med 2009; 15: 152.
15. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74.
16. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527.
17. Weber C, Belge KU, von Hundelshausen P, et al. Differential che-mokine receptor expression and function in human monocyte sub-populations. J Leukoc Biol 2000; 67: 699.
18. ++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536.
19. Frankenberger M, Sternsdorf T, Pechumer H, et al. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood 1996; 87: 373.
20. Janols H, Bredberg A, Thuvesson I, et al. Lymphocyte and mono-cyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infect Dis 2010; 10: 205.
21. Wijngaarden S, van Roon JA, Bijlsma JW, et al. Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. Rheumatology (Oxford) 2003; 42: 681.
22. + monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419.
23. + monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant 2008; 8: 103.
24. + monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun 1998; 66: 2782.
25. Scherberich JE, Estner H, Segerer W. Impact of different immuno-suppressive regimens on antigen-presenting blood cells in kidney transplant patients. Kidney Blood Press Res 2004; 27: 177.
26. Sester U, Sester M, Heine G, et al. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402.
27. + blood monocytes in patients with chronic renal failure undergoing dialysis: possible involvement of macrophage colony-stimulating factor. Acta Haematol 2001; 105: 21.
28. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303.
29. Martinez FO, Helming L, Gordon S. Alternative activation of mac-rophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451.
30. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677.
31. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958.
32. Cao Q, Zheng D, Wang YP, et al. Macrophages and dendritic cells for treating kidney disease. Nephron Exp Nephrol 2011; 117: e47.
33. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenviron-mental influences. J Immunol 2005; 175: 342.
34. Edwards JP, Zhang X, Frauwirth KA, et al. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80: 1298.
35. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731.
36. Segerer S, Heller F, Lindenmeyer MT, et al. Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int 2008; 74: 37.
37. Woltman AM, de Fijter JW, Zuidwijk K, et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007; 71: 1001.
38. Hayry P, von Willebrand E. Monitoring of human renal allograft rejection with fine-needle aspiration cytology. Scand J Immunol 1981; 13: 87.
39. Om A, Baquero A, Raja R, et al. The prognostic significance of the presence of monocytes in glomeruli of renal transplant allografts. Transplant Proc 1987; 19: 1618.
40. Ramos EL, Barri YM, Croker BP, et al. Thromboxane synthase expression in renal transplant patients with rejection. Transplantation 1995; 59: 490.
41. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582.
42. Pilmore HL, Painter DM, Bishop GA, et al. Early up-regulation of macrophages and myofibroblasts: a new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 2658.
43. Ozdemir BH, Ozdemir FN, Gungen Y, et al. Role of macrophages and lymphocytes in the induction of neovascularization in renal al-lograft rejection. Am J Kidney Dis 2002; 39: 347.
44. Burkhardt K, Bosnecker A, Hillebrand G, et al. MRP8/14-positive macrophages as early acute cellular rejection markers, and soluble MRP8/14 and increased expression of adhesion molecules following renal transplantation. Transplant Proc 1995; 27: 890.
45. Ozdemir BH, Demirhan B, Gungen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. Nephron 2002; 90: 442.
46. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63: 1888.
47. Sund S, Reisaeter AV, Scott H, et al. Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies. Clin Nephrol 2004; 62: 121.
48. Fahim T, Bohmig GA, Exner M, et al. The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant 2007; 7: 385.
49. Harry TR, Coles GA, Davies M, et al. The significance of mono-cytes in glomeruli of humanrenal transplants. Transplantation 1984; 37: 70.
50. Raftery MJ, Seron D, Koffman G, et al. The relevance of induced class II HLA antigens and macrophage infiltration in early renal al-lograft biopsies. Transplantation 1989; 48: 238.
51. Copin MC, Noel C, Hazzan M, et al. Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute rejection of renal allografts. Transpl Immunol 1995; 3: 229.
52. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63: 374.
53. Qi F, Adair A, Ferenbach D, et al. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 2008; 86: 1267.
54. Jose MD, Ikezumi Y, van Rooijen N, et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76(7): 1015.
55. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
56. Ozdemir BH, Ozdemir AA, Sezer S, et al. Influence of 1, 25-dihydroxyvitamin D3 on human leukocyte antigen-DR expression, macrophage infiltration, and graft survival in renal allografts. Transplant Proc 2011; 43: 500.
57. Hutchinson JA, Riquelme P, Sawitzki B, et al. Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187: 2072.
58. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int 2004; 66: 542.
59. Ko GJ, Boo CS, Jo SK, et al. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008; 23: 842.
60. Mrug M, Zhou J, Woo Y, et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 2008; 73: 63.
61. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
62. Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997; 63: 414.
63. Prodjosudjadi W, Daha MR, Gerritsma JS, et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996; 11: 1096.
64. Van Kooten C, Boonstra JG, Paape ME, et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9: 1526.
65. Mayer V, Hudkins KL, Heller F, et al. Expression of the chemokine receptor CCR1 in human renal allografts. Nephrol Dial Transplant 2007; 22: 1720.
66. Williams GT, Smith CA, Spooncer E, et al. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76.
67. Singh KA, Kampen RL, Hoffmann SC, et al. Renal epithelial cell-derived monocyte colony stimulating factor as a local informant of renal injury and means of monocyte activation. Transpl Int 2009; 22: 730.
68. Hoffmann SC, Kampen RL, Amur S, et al. Molecular and immu-nohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002; 74: 916.
69. Biancone L, Segoloni G, Turello E, et al. Expression of inducible lymphocyte costimulatory molecules in human renal allograft. Nephrol Dial Transplant 1998; 13: 716.
70. Denton MD, Geehan CS, Alexander SI, et al. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. J Exp Med 1999; 190: 555.
71. Sayegh MH, Krensky AM. Novel immunotherapeutic strategies using MHC derived peptides. Kidney Int Suppl 1996; 53: S13.
72. Le Meur Y, Jose MD, Mu W, et al. Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Transplantation 2002; 73: 1318.
73. Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281.
74. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.
75. Kutukculer N, Shenton BK, Clark K, et al. Renal allograft rejection: the temporal relationship and predictive value of plasma TNF (alpha and beta), IFN-gamma and soluble ICAM-1. Transpl Int 1995; 8: 45.
76. Abdallah AN, Billes MA, Attia Y, et al. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endo-myocardial biopsy. Eur Heart J 1997; 18: 1024.
77. Wyburn K, Wu H, Yin J, et al. Macrophage-derived interleukin-18 in experimental renal allograft rejection. Nephrol Dial Transplant 2005; 20: 699.
78. Halloran PF, Autenried P, Ramassar V, et al. Local T cell responses induce widespread MHC expression. Evidence that IFN-gamma induces its own expressionin remote sites. J Immunol 1992; 148: 3837.
79. Ioannidis I, Hellinger A, Dehmlow C, et al. Evidence for increased nitric oxide production after liver transplantation in humans. Transplantation 1995; 59: 1293.
80. Delphin S, Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline ep-silon promoter: regulation by NF-IL-4, a C/EBP family member and NF-kappa B/p50. J Exp Med 1995; 181: 181.
81. Holan V, Krulova M, Zajicova A, et al. Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol 2002; 38: 989.
82. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft ne-phropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147.
83. Leibovich SJ, Polverini PJ, Fong TW, et al. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide- synthaseYdependent effector mechanism. Proc Natl Acad Sci USA 1994; 91: 4190.
84. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factorYalpha. Nature 1987; 329: 630.
85. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17: 932.
86. Scandling JD, Busque S, Shizuru JA, et al. Induced immune tolerance for kidney transplantation. N Engl J Med 2011; 365: 1359.
87. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162.
88. Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898.
89. Garcia MR, Ledgerwood L, Yang Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010; 120: 2486.
90. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloidY derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1Ydependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116: 5738.
91. Vinuesa E, Hotter G, Jung M, et al. Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol 2008; 214: 104.
92. Wang Y, Wang YP, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290.
93. Wilson HM, Chettibi S, Jobin C, et al. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phe-notype that attenuates glomerular inflammation in vivo. Am J Pathol 2005; 167: 27.
94. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptanceYinducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21: 728.
95. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875.
96. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009; 60: 1210.
97. Hill GS, Delahousse M, Nochy D, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001; 59: 304.
98. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213.
99. Sun HJ, Zhou T, Wang Y, et al. Macrophages and T lymphocytes are the predominant cells in intimal arteritis of resected renal allo-grafts undergoing acute rejection. Transpl Immunol 2011; 25: 42.
100. Burkhardt K, Radespiel-Troger M, Rupprecht HD, et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J Am Soc Nephrol 2001; 12: 1947.
101. Yokoo T, Ohashi T, Utsunomiya Y, et al. Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood 2001; 98: 57.
102. Kluth DC, Ainslie CV, Pearce WP, et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001; 166: 4728.
103. Wilson HM, Stewart KN, Brown PA, et al. Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. Mol Ther 2002; 6: 710.
104. Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237.
105. Takase O, Hirahashi J, Takayanagi A, et al. Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int 2003; 63: 501.
106. Kim HL, Lee DS, Yang SH, et al. The polymorphism of monocyte chemoattractant proteinY1 is associated with the renal disease of SLE. Am J Kidney Dis 2002; 40: 1146.
107. Scian MJ, Maluf DG, Archer KJ, et al. Gene expression changes are associated with loss of kidney graft function and interstitial fibrosis and tubular atrophy: diagnosis versus prediction. Transplantation 2011; 91: 657.
108. Mengel M, Chang J, Kayser D, et al. The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant 2011; 11: 708.
109. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987.
110. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function inkidney transplant biopsies.J AmSoc Nephrol 2009; 20: 1149.
111. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22: 293.
112. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance inhuman kidney transplant recipients: part I. Blood gene expression statistical analysis. J Cell Biochem 2008; 103: 1681.
113. Park W, Griffin M, Grande JP, et al. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation 2007; 83: 1466.
114. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475.
115. Nair R, Fraer M, Agrawal N, et al. Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome. Transplant Proc 2010; 42: 3507.
116. De Serres SA, Vadivel N, Mfarrej BG, et al. Monocyte-secreted inflammatory cytokines are associated with transplant glomerulopathy in renal allograft recipients. Transplantation 2011; 91: 552.
117. Sadeghi M, Daniel V, Naujokat C, et al. Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin Transplant 2010; 24: 415.
118. Dikow R, Becker LE, Schaier M, et al. In renal transplants with delayed graft function chemokines and chemokine receptor expression predict long-term allograft function. Transplantation 2010; 90: 771.
119. Khan F, Sar A, Gonul I, et al. Graft inflammation and histologic indicators of kidney chronic allograft failure: low-expressing interleukin-10 genotypes cannot be ignored. Transplantation 2010; 90: 630.
120. Dalton RS, Webber JN, Pead P, et al. Immunomonitoring of renal transplant recipients in the early posttransplant period by sequential analysis of chemokine and chemokine receptor gene expression in peripheral blood mononuclear cells. Transplant Proc 2005; 37: 747.
121. Le Meur Y, Leprivey-Lorgeot V, Mons S, et al. Serum levels of macrophage-colony stimulating factor (M-CSF): a marker of kidney allograft rejection. Nephrol Dial Transplant 2004; 19: 1862.
122. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glo-merular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90: 1478.
123. Hoffmann U, Bergler T, Segerer S, et al. Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transpl Immunol 2010; 23: 204.